Tissue | Expression Dynamics | Abbreviation |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004217627 | Esophagus | HGIN | regulation of protein catabolic process | 119/2587 | 391/18723 | 8.09e-18 | 2.43e-15 | 119 |
GO:001049826 | Esophagus | HGIN | proteasomal protein catabolic process | 139/2587 | 490/18723 | 1.20e-17 | 3.41e-15 | 139 |
GO:004586227 | Esophagus | HGIN | positive regulation of proteolysis | 107/2587 | 372/18723 | 2.61e-14 | 4.60e-12 | 107 |
GO:004316126 | Esophagus | HGIN | proteasome-mediated ubiquitin-dependent protein catabolic process | 114/2587 | 412/18723 | 7.00e-14 | 1.20e-11 | 114 |
GO:190336227 | Esophagus | HGIN | regulation of cellular protein catabolic process | 81/2587 | 255/18723 | 1.16e-13 | 1.93e-11 | 81 |
GO:000989626 | Esophagus | HGIN | positive regulation of catabolic process | 126/2587 | 492/18723 | 1.46e-12 | 2.09e-10 | 126 |
GO:003133126 | Esophagus | HGIN | positive regulation of cellular catabolic process | 112/2587 | 427/18723 | 5.15e-12 | 6.72e-10 | 112 |
GO:190305027 | Esophagus | HGIN | regulation of proteolysis involved in cellular protein catabolic process | 70/2587 | 221/18723 | 6.21e-12 | 7.76e-10 | 70 |
GO:006113627 | Esophagus | HGIN | regulation of proteasomal protein catabolic process | 60/2587 | 187/18723 | 1.10e-10 | 1.12e-08 | 60 |
GO:004573227 | Esophagus | HGIN | positive regulation of protein catabolic process | 69/2587 | 231/18723 | 1.66e-10 | 1.64e-08 | 69 |
GO:200005827 | Esophagus | HGIN | regulation of ubiquitin-dependent protein catabolic process | 53/2587 | 164/18723 | 9.89e-10 | 8.13e-08 | 53 |
GO:190336427 | Esophagus | HGIN | positive regulation of cellular protein catabolic process | 51/2587 | 155/18723 | 1.01e-09 | 8.15e-08 | 51 |
GO:001050616 | Esophagus | HGIN | regulation of autophagy | 84/2587 | 317/18723 | 1.39e-09 | 1.08e-07 | 84 |
GO:190180020 | Esophagus | HGIN | positive regulation of proteasomal protein catabolic process | 41/2587 | 114/18723 | 2.25e-09 | 1.67e-07 | 41 |
GO:190305219 | Esophagus | HGIN | positive regulation of proteolysis involved in cellular protein catabolic process | 45/2587 | 133/18723 | 3.55e-09 | 2.53e-07 | 45 |
GO:000697927 | Esophagus | HGIN | response to oxidative stress | 107/2587 | 446/18723 | 3.91e-09 | 2.76e-07 | 107 |
GO:003243427 | Esophagus | HGIN | regulation of proteasomal ubiquitin-dependent protein catabolic process | 45/2587 | 134/18723 | 4.64e-09 | 3.12e-07 | 45 |
GO:003243620 | Esophagus | HGIN | positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 32/2587 | 90/18723 | 1.71e-07 | 8.47e-06 | 32 |
GO:200006025 | Esophagus | HGIN | positive regulation of ubiquitin-dependent protein catabolic process | 34/2587 | 107/18723 | 1.46e-06 | 5.56e-05 | 34 |
GO:006219727 | Esophagus | HGIN | cellular response to chemical stress | 76/2587 | 337/18723 | 8.00e-06 | 2.41e-04 | 76 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501239 | Esophagus | HGIN | Parkinson disease | 124/1383 | 266/8465 | 5.95e-32 | 9.70e-30 | 7.70e-30 | 124 |
hsa0520839 | Esophagus | HGIN | Chemical carcinogenesis - reactive oxygen species | 92/1383 | 223/8465 | 2.41e-19 | 9.83e-18 | 7.80e-18 | 92 |
hsa0412026 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
hsa0541839 | Esophagus | HGIN | Fluid shear stress and atherosclerosis | 42/1383 | 139/8465 | 2.92e-05 | 3.81e-04 | 3.02e-04 | 42 |
hsa05012114 | Esophagus | HGIN | Parkinson disease | 124/1383 | 266/8465 | 5.95e-32 | 9.70e-30 | 7.70e-30 | 124 |
hsa05208115 | Esophagus | HGIN | Chemical carcinogenesis - reactive oxygen species | 92/1383 | 223/8465 | 2.41e-19 | 9.83e-18 | 7.80e-18 | 92 |
hsa04120111 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
hsa05418115 | Esophagus | HGIN | Fluid shear stress and atherosclerosis | 42/1383 | 139/8465 | 2.92e-05 | 3.81e-04 | 3.02e-04 | 42 |
hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa05012211 | Esophagus | ESCC | Parkinson disease | 201/4205 | 266/8465 | 1.56e-18 | 8.72e-17 | 4.46e-17 | 201 |
hsa05208211 | Esophagus | ESCC | Chemical carcinogenesis - reactive oxygen species | 168/4205 | 223/8465 | 1.83e-15 | 6.81e-14 | 3.49e-14 | 168 |
hsa05418211 | Esophagus | ESCC | Fluid shear stress and atherosclerosis | 109/4205 | 139/8465 | 2.00e-12 | 3.72e-11 | 1.90e-11 | 109 |
hsa0522518 | Esophagus | ESCC | Hepatocellular carcinoma | 109/4205 | 168/8465 | 4.27e-05 | 1.88e-04 | 9.64e-05 | 109 |
hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa05012310 | Esophagus | ESCC | Parkinson disease | 201/4205 | 266/8465 | 1.56e-18 | 8.72e-17 | 4.46e-17 | 201 |
hsa05208310 | Esophagus | ESCC | Chemical carcinogenesis - reactive oxygen species | 168/4205 | 223/8465 | 1.83e-15 | 6.81e-14 | 3.49e-14 | 168 |
hsa05418310 | Esophagus | ESCC | Fluid shear stress and atherosclerosis | 109/4205 | 139/8465 | 2.00e-12 | 3.72e-11 | 1.90e-11 | 109 |
hsa0522519 | Esophagus | ESCC | Hepatocellular carcinoma | 109/4205 | 168/8465 | 4.27e-05 | 1.88e-04 | 9.64e-05 | 109 |
hsa0501214 | Liver | Cirrhotic | Parkinson disease | 158/2530 | 266/8465 | 3.62e-24 | 6.02e-22 | 3.71e-22 | 158 |
hsa0520822 | Liver | Cirrhotic | Chemical carcinogenesis - reactive oxygen species | 121/2530 | 223/8465 | 1.35e-14 | 4.08e-13 | 2.52e-13 | 121 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KEAP1 | SNV | Missense_Mutation | | c.349G>A | p.Glu117Lys | p.E117K | Q14145 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-85-8354-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
KEAP1 | SNV | Missense_Mutation | novel | c.176N>G | p.His59Arg | p.H59R | Q14145 | protein_coding | deleterious(0.01) | probably_damaging(0.963) | TCGA-90-7964-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
KEAP1 | SNV | Missense_Mutation | novel | c.919N>A | p.Glu307Lys | p.E307K | Q14145 | protein_coding | deleterious(0.03) | benign(0.027) | TCGA-92-7340-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
KEAP1 | SNV | Missense_Mutation | novel | c.1772N>T | p.Trp591Leu | p.W591L | Q14145 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-92-8063-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Chemotherapy | taxol | SD |
KEAP1 | SNV | Missense_Mutation | novel | c.344N>A | p.Leu115Gln | p.L115Q | Q14145 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-94-8490-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
KEAP1 | SNV | Missense_Mutation | | c.959N>A | p.Arg320Gln | p.R320Q | Q14145 | protein_coding | deleterious(0) | possibly_damaging(0.889) | TCGA-98-A539-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
KEAP1 | SNV | Missense_Mutation | novel | c.660N>A | p.Phe220Leu | p.F220L | Q14145 | protein_coding | tolerated(0.07) | benign(0.066) | TCGA-MF-A522-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | PD |
KEAP1 | SNV | Missense_Mutation | | c.1661G>A | p.Arg554Gln | p.R554Q | Q14145 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-O2-A52Q-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
KEAP1 | SNV | Missense_Mutation | novel | c.404N>A | p.Arg135His | p.R135H | Q14145 | protein_coding | deleterious(0.01) | probably_damaging(0.989) | TCGA-XC-AA0X-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KEAP1 | insertion | Frame_Shift_Ins | novel | c.966_967insT | p.Lys323Ter | p.K323* | Q14145 | protein_coding | | | TCGA-55-6970-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
9817 | KEAP1 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR BINDING | inhibitor | CHEMBL1762621 | BARDOXOLONE METHYL | |
9817 | KEAP1 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR BINDING | inhibitor | 252827430 | | |
9817 | KEAP1 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR BINDING | | 135650061 | BARDOXOLONE | |
9817 | KEAP1 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR BINDING | inhibitor | CHEMBL2107333 | DIMETHYL FUMARATE | |
9817 | KEAP1 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR BINDING | | 385612246 | | |
9817 | KEAP1 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR BINDING | | 385612247 | | |
9817 | KEAP1 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR BINDING | | DIMETHYL FUMARATE | DIMETHYL FUMARATE | 23647822 |
9817 | KEAP1 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR BINDING | | 348353669 | | |
9817 | KEAP1 | ENZYME, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR BINDING | | 375973258 | | |